Characterization of currently marketed heparin products: composition analysis by 2D-NMR†
Abstract
Each type of
Maintenance work is planned from 09:00 BST to 12:00 BST on Saturday 28th September 2024.
During this time the performance of our website may be affected - searches may run slowly, some pages may be temporarily unavailable, and you may be unable to access content. If this happens, please try refreshing your web browser or try waiting two to three minutes before trying again.
We apologise for any inconvenience this might cause and thank you for your patience.
* Corresponding authors
a
Food & Drug Administration, CDER, Division of Pharmaceutical Analysis, 1114 Market St, St. Louis, MO 63101, USA
E-mail:
David.Keire@fda.hhs.gov
Tel: +1 314 539 3850
b
Food & Drug Administration, CDER, Office of New Drug Quality Assessment, WO21 RM2524, 10903 New Hampshire, Silver Spring, USA
E-mail:
ali.alhakim@fda.hhs.gov
Fax: +1 301 796 9747
Tel: +1 301 796 1323
Each type of
D. A. Keire, L. F. Buhse and A. al-Hakim, Anal. Methods, 2013, 5, 2984 DOI: 10.1039/C3AY40226F
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content